Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Adenocarcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma
Interventions: DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel
Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)